Cibus Biotechnologies and Ioniq Sciences

May 16, 2021

Cibus Biotechnologies (Cibus) owns an exclusive world-wide license for technology developed at the University of Arizona that could potentially stop a virus’ ability to replicate. Multiple patents were filed in 2019. It is anticipated that additional patents will be filed as work continues. The initial viral targets will be White Spot SyndromeVirus and African Swine Fever.

ONIQ Sciences, Inc. is developing advanced multi-cancer screening technology for early detection that will expand the therapeutic window, dramatically improve survivability, and reduce the cost of healthcare. IONIQ Science’s first product utilizing its proprietary analytic platform, the ProLung Test™for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. ProLung rebranded to IONIQSciences in May 2020.